The Panova 3 trial proved TTFields' benefit with a gemcitabine-based chemotherapy. However, with up to 50% of patients receiving the FOLFIRINOX regimen, it is unknown if TTFields provide the same survival benefit when combined with this common alternative, representing a critical evidence gap for clinicians.

Dr. Levin reframes cancer as a cognitive problem where the bioelectric "glue" binding cells into a collective fails. Cells lose their large-scale purpose and revert to an ancient, single-cell state. Restoring this electrical communication can normalize tumors without killing the cells, presenting a non-destructive therapeutic approach.

The FDA-approved Optune device, which uses tumor-treating fields, significantly improved median overall survival and pain-free survival for patients with locally advanced, unresectable pancreatic cancer when added to chemotherapy, offering a new non-invasive treatment option.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

While approved for locally advanced pancreatic cancer, experts are already questioning its potential in broader applications. Future research could explore using TTFields for low-volume metastatic disease or in older patients unfit for surgery, suggesting the current approval may be a starting point for expanded use.

Unlike systemic treatments, which rarely cause pancreatic tumors to shrink on scans, TAMP is demonstrating meaningful radiographic responses. This includes resolving major vessel narrowing, suggesting a more potent local effect and hinting at its potential for converting patients to resectability.

The future of treating advanced pancreatic cancer involves innovative, localized approaches beyond systemic chemotherapy. These include phototherapy to destroy tumor tissue around key blood vessels and transarterial perfusion for direct chemotherapy delivery, aiming to make more patients operable and improve outcomes.

Clinical data revealed a surprising synergy: patients receiving TAMP after chemoradiation had a 60% two-year survival rate. The theory is that radiation remodels the tumor's microvasculature, reducing drug washout and effectively 'priming' the tumor for this regional therapy.

The dense stromal tissue surrounding pancreatic tumors acts as a physical barrier, protecting cancer cells from chemotherapy and immune cells. Varistem's FAK inhibitor, defactinib, targets this microenvironment by reducing fibroblasts and collagen. This "softens up" the tumor, allowing T-cells and other therapeutic agents to penetrate and attack the cancer more effectively.